Clinical Trial Update: Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003 [Phase 2]

View source ↗

Summary

Phase 2 open-label extension evaluating longer-term efficacy and safety of LIB003 in hypercholesterolemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• LIB003

Snippet

Sponsor: LIB Therapeutics LLC | Conditions: Hypercholesterolemia | Phase 2 | Status: COMPLETED | Results posted: 2022-02-10